- Home
- RLAY vs TRVI Comparison
RLAY vs TRVI Comparison
Compare RLAY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- TRVI
- Stock Information
- Founded
- RLAY 2015
- TRVI 2011
- Country
- RLAY United States
- TRVI United States
- Employees
- RLAY N/A
- TRVI N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- TRVI Health Care
- Exchange
- RLAY Nasdaq
- TRVI Nasdaq
- Market Cap
- RLAY 610.3M
- TRVI 725.7M
- IPO Year
- RLAY 2020
- TRVI 2019
- Fundamental
- Price
- RLAY $3.54
- TRVI $7.52
- Analyst Decision
- RLAY Strong Buy
- TRVI Strong Buy
- Analyst Count
- RLAY 12
- TRVI 9
- Target Price
- RLAY $18.45
- TRVI $19.50
- AVG Volume (30 Days)
- RLAY 2.8M
- TRVI 1.7M
- Earning Date
- RLAY 08-07-2025
- TRVI 08-07-2025
- Dividend Yield
- RLAY N/A
- TRVI N/A
- EPS Growth
- RLAY N/A
- TRVI N/A
- EPS
- RLAY N/A
- TRVI N/A
- Revenue
- RLAY $8,355,000.00
- TRVI N/A
- Revenue This Year
- RLAY $17.59
- TRVI N/A
- Revenue Next Year
- RLAY N/A
- TRVI N/A
- P/E Ratio
- RLAY N/A
- TRVI N/A
- Revenue Growth
- RLAY N/A
- TRVI N/A
- 52 Week Low
- RLAY $1.78
- TRVI $2.36
- 52 Week High
- RLAY $10.72
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- RLAY 52.25
- TRVI 59.76
- Support Level
- RLAY $3.31
- TRVI $6.55
- Resistance Level
- RLAY $3.61
- TRVI $7.66
- Average True Range (ATR)
- RLAY 0.21
- TRVI 0.36
- MACD
- RLAY -0.02
- TRVI -0.04
- Stochastic Oscillator
- RLAY 68.67
- TRVI 81.51
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.